India’s Dr. Reddy’s Seen Hit Most From Try To Ban Favored Generics

A piece of U.S. legislation could have a large negative impact on Indian generics maker Dr. Reddy's Laboratories. U.S. Congress is considering a bill that would have the effect of banning the transfer of authorized generics rights from multinational pharmaceutical companies to a third party. In particular, the measure would have a negative impact on Dr. Reddy's approved generic of GlaxoSmithKline's Imitrex (sumatriptan) for migraines, which the firm launched last November. Among the beneficiaries could be generics makers such as Cipla, Sun Pharma and others not chosen by GSK as the generics-maker of choice. (Click here for more